Observational analysis shows CAR-T cell therapy improves outcomes in multiple hematological malignancies, indicating its potential in solid tumors.
CAR-T cell therapy has been proven to show favorable efficacy in various hematological malignancies, particularly in acute lymphoblastic leukemia, multiple myeloma, and myelodysplastic syndromes, with promising results also observed in chronic lymphocytic leukemia. Additionally, CAR-T cell therapy can be applied in the treatment of multiple diseases such as hematological tumors and solid tumors, independent of factors including tumor type, patient age, tumor stage, and treatment response. This article outlines the definition, development history, basic principles of CAR-T cell therapy, and its significance in tumor treatment. It further discusses in detail the structure and function of CAR-T cells, their preparation process, clinical applications, safety, and side effects. Finally, the prospects and future directions of CAR-T cell therapy are explored.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: